Taisuke Tsuji1, Kazunari Tsuyuguchi2, Kazunobu Tachibana3, Yohei Kimura4, Takehiko Kobayashi5, Shojiro Minomo6, Shinji Atagi7, Akihide Matsumura8, Seiji Hayashi9, Katsuhiro Suzuki10. 1. Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: tsujita@kch.hosp.go.jp. 2. Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: tsuyuguchi@kch.hosp.go.jp. 3. Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: ktachiba@kch.hosp.go.jp. 4. Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: youhei-kimuta@hosp.go.jp. 5. Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: t-kobayashi@kch.hosp.go.jp. 6. Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: s-minomo@kch.hosp.go.jp. 7. Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: s-atagi@kch.hosp.go.jp. 8. Department of Surgery, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: a-matsumura@kch.hosp.go.jp. 9. Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: shayashi@kch.hosp.go.jp. 10. Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan. Electronic address: ksuzuki@kch.hosp.go.jp.
Abstract
BACKGROUND: Although nontuberculous mycobacteria (NTM) lung diseases can occur in association with lung cancer, no study has evaluated the effect of lung cancer treatment on NTM lung diseases. Therefore, the present study aimed to retrospectively examine the effect of lung cancer treatment on NTM lung diseases. METHODS: Patients diagnosed with NTM lung diseases in combination with cytologically or histologically proven lung cancer between January 1, 2010 and October 31, 2014 were enroled. The clinical history of eligible patients was retrospectively reviewed. RESULTS: Seven hundred twenty-eight patients were diagnosed with NTM lung diseases. Among these patients, 29 (3.9%) also had lung cancer. Of the 29 patients with NTM and lung cancer, 62% had Mycobacterium avium complex as the pathogenic organism. The most common lung cancer histology was adenocarcinoma (62.1%). Anti-cancer cytotoxic chemotherapy was administered to seven patients, and the two patients who did not receive NTM treatment showed worsening of their NTM lung disease. CONCLUSION: Whether NTM lung disease should be treated during anti-cancer chemotherapy has not been not clarified by this study. Induction of anti-NTM therapy should be made after careful consideration, because the duration of anti-NTM treatment is long and anti-mycobacterial drugs have extensive effects on anti-cancer drugs. However, we think that anti-NTM therapy should be introduced after consideration of the worsening of symptoms and radiological findings associated with NTM lung disease.
BACKGROUND: Although nontuberculous mycobacteria (NTM) lung diseases can occur in association with lung cancer, no study has evaluated the effect of lung cancer treatment on NTM lung diseases. Therefore, the present study aimed to retrospectively examine the effect of lung cancer treatment on NTM lung diseases. METHODS:Patients diagnosed with NTM lung diseases in combination with cytologically or histologically proven lung cancer between January 1, 2010 and October 31, 2014 were enroled. The clinical history of eligible patients was retrospectively reviewed. RESULTS: Seven hundred twenty-eight patients were diagnosed with NTM lung diseases. Among these patients, 29 (3.9%) also had lung cancer. Of the 29 patients with NTM and lung cancer, 62% had Mycobacterium avium complex as the pathogenic organism. The most common lung cancer histology was adenocarcinoma (62.1%). Anti-cancer cytotoxic chemotherapy was administered to seven patients, and the two patients who did not receive NTM treatment showed worsening of their NTM lung disease. CONCLUSION: Whether NTM lung disease should be treated during anti-cancer chemotherapy has not been not clarified by this study. Induction of anti-NTM therapy should be made after careful consideration, because the duration of anti-NTM treatment is long and anti-mycobacterial drugs have extensive effects on anti-cancer drugs. However, we think that anti-NTM therapy should be introduced after consideration of the worsening of symptoms and radiological findings associated with NTM lung disease.